"Partners in innovation: PDPs and the future of public-private collaborations", Workshop

Past Event

13 June 2012, 10:00am - 6:00pm


This invitation only workshop is hosted by the BioProperty research group at the Institute for Science, Innovation and Society

Summary: Global Product Development Partnerships (PDPs) for new health technologies have been a key organisational innovation in global health research and development. These partnerships bring together global philanthropic foundations, national governments, international health organisations, non-governmental groups and academic researchers, and have introduced fundamental changes in the way drugs for tropical diseases are developed, priced, distributed and promoted.

PDPs are constantly evolving, however, as befits the complexity of the challenges to be tackled. Recent trends towards a consolidation of PDPs, the changing emphases and priorities of donors, and the experience gained from years of collaborative drug development are prompting a re-examination of the ways in which these heterogeneous actors collaborate.
This one-day workshop will offer a venue for discussion of the past, present and future of PDPs for research and development on neglected diseases. It will bring together experts from partnerships, medical research organisations, funding agencies, and academia to discuss the challenges of multi-party international ventures in global health.


  • Nick Cammack, Senior Vice-President and Head, Medicines Development Campus for Diseases of the Developing World at GSK, Tres Cantos, Spain
  • Jennifer Dent, Vice President for Commercialization and Alliance Management, BIO Ventures for Global Health
  • Javier Guzman, Director of Research, Policy Cures
  • Sue Kinn, Team Leader and Research Manager, UK Department for International Development
  • Ole F. Olesen, Senior Scientific Officer, Directorate for Health, European Commission
  • Jean-Pierre Paccaud, Director Business Development, Drugs for Neglected Diseases initiative (DNDi) Anya Ramalho, Head of Business Development, Medicines for Malaria Venture (MMV)
  • Marcel Tanner, Director, Swiss Tropical and Public Health Institute